ME - CONSENSUS CO - 23andMe Holding Co.

23andMe Holding Co. (ME) is currently fighting for survival, losing valuable bioinformatics specialists due to mass layoffs. The business is suffering from declining interest in genetics and severe pricing pressure from competitors. The price action, recorded at , illustrates the position of a company that relies on a unique genomic dataset to collaborate with pharmaceutical behemoths in drug development.

This indicator aggregates expert expectations regarding the asset's fair value, identifying deviations of the market price from the fundamentally justified average. By analyzing the market's average target price, an investor assesses the capitalization potential of 23andMe Holding Co. (ME), which is based on the value of unique genetic databases and the expertise of leading data scientists in the field of personalized medicine.